Clinical Trials Browser

Active not recruiting × Has announcements × Lymphoma, Large B-Cell, Diffuse × Clear all

NCT02227251 2026-05-06

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Active not recruiting

244 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04404283 2026-04-20

ECHELON-3

Phase 3 Active not recruiting

239 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse